Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Boehringer Ingelheim's anti-CD33 MAb enters phase I AML study

Dec. 18, 2012

Treatment begins in first phase II trial of IPH-2102 for AML

Dec. 18, 2012

Immunomedics develops antibodies with potential in the therapeutic intervention of lymphoma

Dec. 14, 2012

Adaptimmune presents gene-engineered autologous T cells for multiple myeloma

Dec. 14, 2012

KaloBios Pharmaceuticals KB-003 for chronic myelomonocytic leukemia

Dec. 13, 2012

Stemline Therapeutics describes MAb conjugate against IL-3R-alpha

Dec. 13, 2012

OncoTherapy Science provides update on COMPETE-PC study

Dec. 12, 2012

Clinical studies presented for circularly permuted TRAIL in MM

Dec. 11, 2012

Roche submits line extension application to the EMA for MabThera

Dec. 11, 2012

Inovio Pharmaceuticals reports data from trial of its electroporation vaccine delivery system

Dec. 11, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...